Has Cheneen Sykes received payments from drug or device companies?

Yes. Drug and device makers reported $6,751 in general payments to Cheneen Sykes across 308 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Cheneen Sykes did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Cheneen Sykes come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Cheneen Sykes

Psychiatric/Mental Health · Buffalo, NYNPI 1821452327

Payments from drug & device makers

$6,751in general payments, 2019–2025

Across 308 payments — averaging $21.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Teva Pharmaceuticals USA, Inc.$1K
AbbVie$950
Alkermes, Inc.$776
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$648
Johnson & Johnson$566
Neurocrine Biosciences, Inc.$531
plus $2K from 16 others

What the payments were for

Food & beverage$6,65599%
Education$961%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Teva Pharmaceuticals USA, Inc.	64	$1,234
AbbVie	47	$950
Alkermes, Inc.	28	$776
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	28	$648
Johnson & Johnson	16	$566
Neurocrine Biosciences, Inc.	25	$531
Lundbeck LLC	18	$322
Axsome Therapeutics, Inc.	9	$266
Bausch Health US, LLC	13	$219
Takeda Pharmaceuticals U.S.A., Inc.	11	$209
Otsuka America Pharmaceutical, Inc.	9	$180
Almatica Pharma LLC	8	$160
Supernus Pharmaceuticals, Inc.	8	$149
Vanda Pharmaceuticals Inc.	5	$124
Sunovion Pharmaceuticals Inc.	5	$113
Corium, LLC	4	$73
Avanir Pharmaceuticals, Inc.	2	$46
Alfasigma USA, Inc.	1	$44
Biogen	2	$42
Idorsia Pharmaceuticals US Inc	2	$40
E.r. Squibb & Sons, L.L.C.	2	$39
Eisai Inc.	1	$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LYBALVI$430
SPRAVATO$145

How this compares

$6,751 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
CaplytaLumateperone Tosylate	12	$22,097
TrintellixVortioxetine Hydrobromide	13	$6,082
Aripiprazole	17	$1,931
Bupropion XlBupropion Hcl	47	$1,770
Atomoxetine Hcl	12	$1,411
Duloxetine Hcl	49	$1,120
Escitalopram Oxalate	37	$879
Buspirone Hcl	46	$838
Olanzapine	19	$611
Venlafaxine Hcl ErVenlafaxine Hcl	42	$527
Oxcarbazepine	12	$460
Trazodone Hcl	50	$416
Lamotrigine	45	$414
Quetiapine Fumarate	14	$388
Diazepam	29	$373

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta	$648	$22,09712 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix	$209	$6,08213 claims
Almatica Pharma LLCSertraline Hcl	$160	$8511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Buffalo

Carl de FrancoBuffalo$28K
Sarah OtwellBuffalo$15K
Tisha TanyiBuffalo$10K
Richard ZawislakBuffalo$10K
Glenn HannDansville$1.3M
Tammy RussoNiskayuna$568K
Carrie EdickSchenectady$484K
Eric SpronzCentereach$448K
Terry Jo Brooks-DevlinTonawanda$176K
Kevin SiewersStaten Island$155K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →